UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Therapeutic application of monoclonal antibodies in cancer: advances and challenges

British medical bulletin, 2012-12, Vol.104 (1), p.41-59

2012

Volltextzugriff (PDF)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

British journal of cancer, 2011-11, Vol.105 (10), p.1554-1562

2011

Volltextzugriff (PDF)

A preliminary characterisation of de novo lipogenesis in pancreatic (Capan-1) and liver (HepG2) cancer cell lines

European journal of cancer (1990), 2016-07, Vol.61, p.S106-S106

2016

Volltextzugriff (PDF)

841: Colorectal cancer cells with acquired resistance to anti-EGFR mAb ICR62 remain highly sensitive to treatment with small molecule tyrosine kinase inhibitors

European journal of cancer (1990), 2014-07, Vol.50, p.S204-S205

2014

Volltextzugriff (PDF)

410 Predictive Value of CD44, CD24, CD133 and P-glycoprotein for Response to Treatment With a Pan ErbB Blocker and Gemcitabine in Pancreatic Tumour Cells

European journal of cancer (1990), 2012-07, Vol.48, p.S99-S99

2012

Volltextzugriff (PDF)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10

British journal of cancer, 2012-02, Vol.106 (5), p.883-888

2012

Volltextzugriff (PDF)

PO-043 Development of two novel monoclonal antibodies against overexpressed antigens on pancreatic cancer cells for use in diagnosis and therapy

ESMO open, 2018-07, Vol.3 (Suppl 2), p.A244-A244

2018

Volltextzugriff (PDF)

Molecular therapy of head and neck cancer

Cancer and metastasis reviews, 2005-01, Vol.24 (1), p.129-146

Modjtahedi, Helmout

2005

Volltextzugriff (PDF)

Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?

British journal of cancer, 2005-11, Vol.93 (11), p.1316-1316

2005

Volltextzugriff (PDF)

143 Growth response of human colorectal tumour cell lines to treatment with BIBW2992, an irreversible EGFR/HER1 and HER-2 tyrosine kinase inhibitor

European journal of cancer supplements, 2010, Vol.8 (7), p.51-51

2010

Volltextzugriff (PDF)

The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis

Atherosclerosis, 2006-05, Vol.186 (1), p.38-53

2006

Volltextzugriff (PDF)

489 - A preliminary characterisation of de novo lipogenesis in pancreatic (Capan-1) and liver (HepG2) cancer cell lines

European journal of cancer (1990), 2016-07, Vol.61, p.S106-S106

2016

Volltextzugriff (PDF)

Production of a novel camel single-domain antibody specific for the type III mutant EGFR

Tumor biology, 2004-09, Vol.25 (5-6), p.296-305

2004

Volltextzugriff (PDF)

118 Responses of human pancreatic tumour cells to treatment with anti-EGFR mAb ICR62 and the irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor BIBW2992

European journal of cancer supplements, 2010, Vol.8 (7), p.44-44

2010

Volltextzugriff (PDF)

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

British journal of cancer, 1996-01, Vol.73 (2), p.228-235

1996

Volltextzugriff (PDF)

Production and Characterization of a New Antibody Specific for the Mutant EGF Receptor, EGFRvIII, in Camelus bactrianus

Tumor biology, 2004-07, Vol.25 (4), p.179-187

2004

Volltextzugriff (PDF)

Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells

International journal of oncology, 2008-11, Vol.33 (5), p.1107-1113

2008

Volltextzugriff (PDF)

Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction

British journal of cancer, 1993-02, Vol.67 (2), p.254-261

1993

Volltextzugriff (PDF)

EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaques

Atherosclerosis, 2004-09, Vol.176 (1), p.21-26

2004

Volltextzugriff (PDF)

The Binding of HB-EGF to Tumor Cells Is Blocked by mAbs Which Act as EGF and TGFα Antagonists

Biochemical and biophysical research communications, 1995-02, Vol.207 (1), p.389-397

1995

Volltextzugriff (PDF)

Immunotherapy with antibodies to the EGF receptor

International journal of cancer, 1994, Vol.57 (S8), p.103-107

1994

Volltextzugriff (PDF)

Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer

International journal of oncology, 2005-08, Vol.27 (2), p.317

2005

Volltextzugriff (PDF)

Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase‐9 expression and in vitro invasion

International journal of cancer, 2000-05, Vol.86 (3), p.307-317

2000

Volltextzugriff (PDF)

Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells

Cancer research (Chicago, Ill.), 2000-02, Vol.60 (4), p.1121-1128

2000

Volltextzugriff (PDF)

The role of c- erbB receptors and ligands in head and neck squamous cell carcinoma

Oral Oncology, 2002-10, Vol.38 (7), p.627-640

2002

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(73)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(47)
Science & Technology
(46)
Life Sciences & Biomedicine
(45)
Biological And Medical Sciences
(28)
Medical Sciences
(27)
Animals
(26)
Oncology
(23)
Female
(16)
Mice
(16)
Tumor Cells, Cultured
(16)
Tumors
(14)
Receptor, Epidermal Growth Factor - Immunology
(13)
Receptor, Epidermal Growth Factor - Metabolism
(11)
Cell Division - Drug Effects
(10)
Head And Neck Neoplasms - Pathology
(9)
Immunotherapy
(9)
Life Sciences
(9)
Male
(9)
Rats
(9)
Antineoplastic Agents
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapeutic application of monoclonal antibodies in cancer: advances and challenges

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

A preliminary characterisation of de novo lipogenesis in pancreatic (Capan-1) and liver (HepG2) cancer cell lines

841: Colorectal cancer cells with acquired resistance to anti-EGFR mAb ICR62 remain highly sensitive to treatment with small molecule tyrosine kinase inhibitors

410 Predictive Value of CD44, CD24, CD133 and P-glycoprotein for Response to Treatment With a Pan ErbB Blocker and Gemcitabine in Pancreatic Tumour Cells

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10

PO-043 Development of two novel monoclonal antibodies against overexpressed antigens on pancreatic cancer cells for use in diagnosis and therapy

Molecular therapy of head and neck cancer

Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?

143 Growth response of human colorectal tumour cell lines to treatment with BIBW2992, an irreversible EGFR/HER1 and HER-2 tyrosine kinase inhibitor

The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis

489 - A preliminary characterisation of de novo lipogenesis in pancreatic (Capan-1) and liver (HepG2) cancer cell lines

Production of a novel camel single-domain antibody specific for the type III mutant EGFR

118 Responses of human pancreatic tumour cells to treatment with anti-EGFR mAb ICR62 and the irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor BIBW2992

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

Production and Characterization of a New Antibody Specific for the Mutant EGF Receptor, EGFRvIII, in Camelus bactrianus

Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells

Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction

EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaques

The Binding of HB-EGF to Tumor Cells Is Blocked by mAbs Which Act as EGF and TGFα Antagonists

Immunotherapy with antibodies to the EGF receptor

Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer

Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase‐9 expression and in vitro invasion

Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells

The role of c- erbB receptors and ligands in head and neck squamous cell carcinoma

Suchergebnisse filtern